鼻腔给药 - 最新进展与未来展望。

Nasal drug delivery - recent developments and future prospects.

机构信息

IDentity, 19 Cavendish Crescent North, The Park, Nottingham NG7 1BA, UK.

出版信息

J Control Release. 2012 Jul 20;161(2):254-63. doi: 10.1016/j.jconrel.2012.01.024. Epub 2012 Jan 24.

DOI:10.1016/j.jconrel.2012.01.024

Abstract

The present review sets out to discuss recent developments and prospects of absorption promoters and absorption modulator systems being developed commercially by companies specialising in nasal drug delivery of normal small molecular weight drugs and biological drugs such as peptide and proteins. The absorption promoter systems selected for discussion in this review are those with the most promising preclinical and/or clinical data and sufficient toxicology data and/or company development efforts to warrant use in marketed products i.e. CPE-215 (cyclopenta decalactone (azone)) developed by CPEX Pharma, Intravail (alkylsaccharides) developed by Aegis Therapeutics, ChiSys(TM) (chitosan) and PecSys(TM) (low methylated pectin) in development by Archimedes Pharma and CriticalSorb(TM) (polyglycol mono- and diesters of 12-hydroxystearate (70%), polyethylene glycol (30%)) developed by Critical Pharmaceuticals.

摘要

本综述旨在讨论专门从事普通小分子药物和生物药物（如肽和蛋白质）鼻内给药的公司开发的吸收促进剂和吸收调节剂系统的最新进展和前景。本文选择讨论的吸收促进剂系统是那些具有最有前途的临床前和/或临床数据以及足够的毒理学数据和/或公司开发工作，以保证在市售产品中使用的系统，即 CPEX Pharma 开发的环戊癸内酯（氮酮）、Aegis Therapeutics 开发的 Intravail（烷基糖）、Archimedes Pharma 开发的 ChiSys(TM)（壳聚糖）和 PecSys(TM)（低甲基化果胶）以及 Critical Pharmaceuticals 开发的 CriticalSorb(TM)（聚乙二醇单和二 12-羟基硬脂酸酯（70%）和聚乙二醇（30%））。